Compare LCTX & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | NAUT |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 383.5M |
| IPO Year | 1996 | 2020 |
| Metric | LCTX | NAUT |
|---|---|---|
| Price | $1.32 | $2.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $6.25 | $4.00 |
| AVG Volume (30 Days) | ★ 1.3M | 375.8K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,556,000.00 | N/A |
| Revenue This Year | $109.40 | N/A |
| Revenue Next Year | N/A | $992.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.65 | $0.62 |
| 52 Week High | $2.09 | $4.31 |
| Indicator | LCTX | NAUT |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 52.04 |
| Support Level | $1.14 | $2.28 |
| Resistance Level | $1.80 | $3.17 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 55.56 | 51.72 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.